RA Capital Management, L.P. 13D and 13G filings for Unicycive Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-05-15 4:56 pm Purchase |
2025-03-31 | 13G | Unicycive Therapeutics, Inc. UNCY |
RA Capital Management, L.P. | 1,328,578 9.900% |
176,566 (+15.33%) |
Filing |
| 2025-02-14 6:43 pm Purchase |
2024-12-31 | 13G | Unicycive Therapeutics, Inc. UNCY |
RA Capital Management, L.P. | 1,152,012 9.900% |
104,775 (+10.00%) |
Filing |
| 2024-11-14 5:46 pm Purchase |
2024-09-30 | 13G | Unicycive Therapeutics, Inc. UNCY |
RA Capital Management, L.P. | 1,047,238 9.990% |
700,027 (+201.61%) |
Filing |
| 2024-02-14 6:41 pm Purchase |
2023-12-31 | 13G | Unicycive Therapeutics, Inc. UNCY |
RA Capital Management, L.P. | 347,211 9.990% |
142 (+0.04%) |
Filing |
| 2023-07-06 4:30 pm Purchase |
2023-06-26 | 13G | Unicycive Therapeutics, Inc. UNCY |
RA Capital Management, L.P. | 347,069 9.990% |
347,069 (New Position) |
Filing |